European Study to Describe Hospital Stay in Patients Admitted for Acute Bipolar Manic Episodes

AstraZeneca

Status: Completed

Conditions: Acute Bipolar Manic Episode

Study type: Observational

Funder types: Industry

Identifiers

NCT01239589

NIS-NEU-SER-2010/1

Details and patient eligibility

About

This study is being carried out to find out how patients suffering from the acute manic phase of bipolar disease are currently managed with Quetiapine Immediate Release (IR) or Quetiapine Extended Release (XR) in the hospital setting in real life practice, including length of stay.

Enrollment: 1,280 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients diagnosed with Bipolar Disorder (ICD-10).
• Admitted for acute bipolar manic episode from 1st October 2009 to 1st October 2010
• Patients treated with quetiapine IR or quetiapine XR during the hospitalization period.

Exclusion criteria

• Patients in which BD is not the main reason for hospitalization
• Patients admitted for acute bipolar mania episodes but finally diagnosed with mixed or bipolar disorder not otherwise specified (NOS) episodes
• Patients receiving both quetiapine IR and XR during the same hospitalization period.

Trial design

1,280 participants in 2 patient groups

1

Description:

patients admitted as for an acute bipolar manic episode and treated with quetiapine IR

2

Description:

patients admitted as for an acute bipolar manic episode and treated with quetiapine XR